胸腔穿刺置管联合持续负压吸引治疗微波消融肺结节所致气胸  

Pleuracentesis and catheterization combined with persistent vacuum aspiration for treating pneumothorax caused by microwave ablation of pulmonary nodules

作　　者：冯潇 杨海涛[1] FENG Xiao;YANG Haitao(Department of Thoracic Surgery,the People’s Hospital of Liaoning Province,Shenyang 110016,China)

机构地区：[1]辽宁省人民医院(中国医科大学人民医院)胸外科,辽宁沈阳110016

出　　处：《中国介入影像与治疗学》2024年第10期588-591,共4页Chinese Journal of Interventional Imaging and Therapy

基　　金：辽宁省科学技术计划项目(2023-BSBA-201、2023-MSLH-116)。

摘　　要：目的观察胸腔穿刺置管联合持续负压吸引治疗微波消融(MWA)肺结节所致气胸的价值。方法回顾性分析21例肺结节经MWA后出现气胸而接受胸腔穿刺置管联合持续负压吸引治疗患者,观察胸腔穿刺置管联合持续负压吸引的疗效及安全性。结果胸腔穿刺置管联合持续负压吸引成功率和有效率均为100%(21/21)。胸腔积液发生率为14.29%(3/21),咯血发生率为9.52%(2/21),未见其他并发症。治疗后3个月,肺结节病灶71.43%(15/21)完全缓解,28.57%(6/21)部分缓解,总有效率和局部控制率均为100%(21/21)。结论胸腔穿刺置管联合持续负压吸引治疗MWA肺结节所致气胸安全、有效。Objective To observe the value of pleuracentesis and catheterization combined with persistent vacuum aspiration for treating pneumothorax caused by microwave ablation(MWA)of pulmonary nodules.Methods Totally 21 patients who underwent pleuracentesis and catheterization combined with persistent vacuum aspiration since pneumothorax caused by MWA of pulmonary nodules were enrolled,and the efficacy and safety of pleuracentesis and catheterization combined with persistent vacuum aspiration were observed.Results The success rate and effective rate of pleuracentesis and catheterization combined with persistent vacuum aspiration were both 100%(21/21).The incidence of pleural effusion and hemoptysis was 14.29%(3/21)and 9.52%(2/21),respectively,while no other complication occurred.Three months after treatment,complete remission of pulmonary nodule was observed in 71.43%(15/21)cases,while partial remission was noticed in 28.57%(6/21)cases,and the total effective rate and local control rate of pulmonary nodules were both 100%(21/21).Conclusion Pleuracentesis and catheterization combined with persistent vacuum aspiration was safe and effective for treating pneumothorax caused by MWA of pulmonary nodules.

关 键 词：肺肿瘤 气胸 引流术 中心静脉置管 消融技术 

分 类 号：R561.4[医药卫生—呼吸系统] R815[医药卫生—内科学]